Fermentations of pectin-rich biomass with recombinant bacteria to produce fuel ethanol.

Pectin-rich residues from sugar beet processing contain significant carbohydrates and insignificant amounts of lignin. Beet pulp was evaluated for conversion to ethanol using recombinant bacteria as biocatalysts. Hydrolysis of pectin-rich residues followed by ethanolic fermentations by yeasts has not been productive because galacturonic acid and arabinose are not fermentable to ethanol by these organisms. The three recombinant bacteria evaluated in this study, Escherichia coli strain KO11, Klebsiella oxytoca strain P2, and Erwinia chrysanthemi EC 16 pLOI 555, ferment carbohydrates in beet pulp with varying efficiencies. E. coli KO11 is able to convert pure galacturonic acid to ethanol with minimal acetate production. Using an enzyme loading of 10.5 filter paper units of cellulase, 120.4 polygalacturonase units of pectinase, and 6.4 g of cellobiase (per gram of dry wt sugar beet pulp), with substrate addition after 24 h of fermentation, 40 g of ethanol/L was produced. Other recombinants exhibited lower ethanol yields with increases in acetate and succinate production.

Pharmacokinetics of reconstituted human high-density lipoprotein in pigs after hemorrhagic shock with resuscitation.

OBJECTIVES: Reconstituted human high-density lipoprotein (HDL) can inhibit lipopolysaccharide effects in vivo. The major objectives of this study were to characterize the pharmacokinetics of reconstituted HDL in a stressed large-animal model and to provide preclinical tolerance information in support of use of reconstituted HDL in humans. DESIGN: A randomized, blinded, placebo-controlled trial where each animal received either reconstituted human HDL at a dose of 100 mg/kg (apolipoprotein A-I) or placebo, immediately after hemorrhagic shock and resuscitation. SETTING: Animal laboratory. SUBJECTS: Twelve immature female swine (18 to 25 kg) were studied. INTERVENTIONS: Six to 8 days before shock and study drug administration, animals were anesthesized and catheters were placed in the external jugular vein and abdominal aorta. These catheters were secured to the dorsal surface. On the day of shock, the animals were sedated (alpha-chloralose) and 50 mL/kg of arterial blood was removed over 0.5 hr. One half hour after blood removal, shed blood was infused, which was immediately followed by study drug (reconstituted HDL or placebo), and then by 1 L of lactated Ringer's solution. MEASUREMENTS AND MAIN RESULTS: Physiologic (arterial blood pressure, heart rate, respiratory rate) and laboratory (serum chemistries, hematologic and coagulation studies, and blood gases) measurements were determined intermittently for 96 hrs after the induction of shock. Blood was collected intermittently for 48 hrs after shock for assay of apolipoprotein A-I and phosphatidylcholine in plasma. Reconstituted HDL was well tolerated and did not appear to alter the physiologic responses to shock and resuscitation. HDL transient increase in aspartate aminotransferase concentration was noted in the reconstituted group but this increase normalized by 24 hrs after drug administration. Mean apolipoprotein A-I pharmacokinetic parameters were as follows: half-life 24.5+/-5.3 (SD) hrs; clearance 41.9+/-10 mL/hr; and volume of distribution 1.39+/-0.08 L. The apparent mean half-life of phosphatidylcholine was 5.4+/-0.8 hrs. CONCLUSIONS: Reconstituted human HDL was well tolerated in animals that had undergone hemorrhagic shock with resuscitation. The apolipoprotein component of reconstituted HDL had a relatively long half-life, with distribution limited to the vascular space. These findings support the investigational use of this product in humans.

[Personal computer-assisted "acceptable hemoglobin concentration". An example of preoperative autologous blood donation]. / PC-gestützte Ermittlung der "akzeptablen Hämoglobinkonzentration". Beispiel der präoperativen Eigenblutspende.

At rest, the actual cardiac output (CO) exceeds the CO required to cover the oxygen consumption VO2, provided the hemoglobin level and the non-Hb parameters impacting on cellular oxygen supply (e.g. paO2, pH and body temperature) are normal. The size of this hemodynamic buffer as a function of Hb levels and the non-Hb parameters can be quantified for any clinically conceivable combination including VO2. As Hb levels decrease, the patient's condition is progressively destabilized in the sense that the gradual vanishing of the buffer makes him increasingly sensitive to abnormalities of the non-Hb parameters, such as hypermetabolism, arterial hypoxemia, and alkalosis. This concept is used to illustrate the course of patients participating in an autologous blood predeposit program.

Is there a generally valid, minimum acceptable hemoglobin level?

The different versions of autologous blood transfusion have rekindled interest in a generally valid 'minimum acceptable hemoglobin concentration' of patients around or below 10 g Hb/dl. The adequate Hb concentration capable of covering the oxygen demands of the body depends on several variables measurable at the bedside: oxygen consumption VO2, arterial oxygen tension paO2, body temperature, arterial and mixed venous pH, and cardiac output CO as the most important compensatory variable in anemia. Because of the strain imposed on the myocardium and the coronary circulation, anemia should not raise CO to more than twice the resting value, i.e. less than 10 l/min. Similarly, the mixed venous pO2, as an indicator of tissue oxygenation, should not fall below 35 mm Hg. With these two restrictions, we studied the relationships of the above-mentioned parameters in a computer-supported model. Under otherwise similar conditions, pvO2 falls with an increase in VO2, a decrease in paO2, a decrease in the temperature, an increase in pH, and a decrease in CO. A resting and slightly acidotic patient without other impediments of his cellular oxygen supply--e.g. the patient on chronic hemodialysis--tolerates a Hb level of 6-7 g/dl with a pvO2 barely exceeding 35 mm Hg and a CO approximately 50% above baseline. By contrast, the hypermetabolic and hypoxemic intensive care patient needs Hb levels in the low normal range, i.e. 12-13 g/dl, especially if he is also alkalotic. A generally valid 'minimum acceptable hemoglobin level' does not exist; the adequate Hb concentration is an individual characteristic needing careful attention.(ABSTRACT TRUNCATED AT 250 WORDS)

A controlled trial of colostomy management by natural evacuation, irrigation and foam enema.

Twenty patients entered a prospective controlled trial of colostomy management by three techniques--natural evacuation, colostomy irrigation and foam enema. Every patient spent 2 months using each technique. The mean number of colostomy actions weekly was 17 during natural evacuation, 6 during irrigation and 10 with the enema. There was no significant difference in the time taken to manage the colostomy by each technique. Eighteen patients considered that both irrigation and the foam enema improved the quality of their life, and opted to continue with irrigation on completion of the study. There were no major complications during the trial but leakage of foam and an increase in flatus were problems with the foam enema. It is concluded that patients should be made aware of the alternative methods available for colostomy management and be encouraged to use the method of their choice.

Rowachol--a possible treatment for cholesterol gallstones.

It has been claimed that Rowachol, a proprietary choleretic, is occasionally successful in the treatment of gallstones. In gallstone patients we have examined its effect on the lipid composition of (1) samples of fasting gall bladder bile obtained at the time of cholecystectomy, and (2) T-tube bile on the tenth post-operative day. In a dose of two capsules, three times a day for only 48 hours, Rowachol significantly lowered the cholesterol solubility of both gall bladder (P less than 0.001) and T-tube bile (P less than 0.05). Rowachol in a dose of one capsule three times a day for 48 hours did not alter bile composition, while four capsules four times a day for a similar period caused a significant (P less than 0.05) deterioration in biliary lipid composition. The possible mechanisms of action of Rowachol and their therapeutic implications are discussed.